The Experts below are selected from a list of 2505 Experts worldwide ranked by ideXlab platform

He Huang - One of the best experts on this subject based on the ideXlab platform.

  • Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of Acute myeloid Leukemia relapse after HLA-matched sibling transplantation: a case report
    BMC, 2019
    Co-Authors: Mengqi Jin, He Huang, Yi Luo, Yamin Tan, Aiyun Jin, Luxin Yang, Guoqing Wei
    Abstract:

    Abstract Background Patients with relapsed/refractory Acute myeloid Leukemia after hematopoietic stem cell transplantation (HSCT) have a poor prognosis, with a 2-year survival rate of 14%. The optimal treatment for these patients remains unclear. To treat these patients, we designed a new salvage regimen consisting of decitabine, cladribine, cytarabine, and granulocyte-stimulating factor (D-CLAG). Case presentation Here, we describe a case of Acute Monocytic Leukemia with a complex karyotype in a 38-year-old female patient who relapsed after her first HSCT, which was performed using a matched sibling donor. The patient did not respond to standard induction chemotherapy and subsequently achieved complete remission with the D-CLAG regimen. No severe hematological or extramedullary toxicity was observed. Subsequently, the patient received a second D-CLAG regimen as a bridge therapy and directly underwent haploidentical related HSCT. Following HSCT, the marrow showed complete hematologic and cytogenetic remission. Currently, 1 year after transplantation, the patient’s general condition remains good. Conclusions This case suggests that the D-CLAG regimen can be an option for reinduction in relapsed refractory AML patients as a bridge to transplantation. Nevertheless, further research will be required in the future as this report describes only a single case

  • candida tropicalis arthritis of the knee in a patient with Acute Monocytic Leukemia
    Blood, 2006
    Co-Authors: Jingsong He, Xiujin Ye, Weiyan Zheng, Wenjun Wu, He Huang
    Abstract:

    The patients with malignant hematopathy are the high-risk group of invasive fungal infections (IFI). Candidemia and IFI caused by Candidas in patients with a hematological malignancy are common but Candida arthritis is rare. Here, we reported a case of Candida tropicalis arthritis of the knee that occurred with Acute Monocytic Leukemia during the recovery period of post chemotherapy myelosuppression and agranulocytosis. Case report: A 45-year-old Chinese woman was diagnosed with Acute Monocytic Leukemia with normal caryotype in november 2004. Complete remission was achieved upon completion of 2 courses of induction chemotherapy. Treatment was administered via a Hickman catheter in the left elbow. Two days after phase V consolidation chemotherapy, the patient experienced high fever accompanied by the development of arthritis in the right knee. The diagnosis of Candida tropicalis arthritis of the knee was confirmed by the appearance of Candida tropicalis isolated from the synovial fluid, but no leukemic cells and acid-fast bacilli were found. According to the susceptibility test in vitro, itraconazole and amphotericin B injection were used sequentially for therapy for 4–5 weeks, which effectively inhibited bacterial growth. However, the arthritis relapsed after 4–6 weeks of drug withdrawal. The arthritis was fully resolved after 8 weeks of therapy with fluconazol injection at a dose of 400mg/d and douching articular cavity with amphotericin B once a week. And then sequential therapy with oral fluconazole was commenced. There was no any adverse effect occurrence during the course of treatment. Discussion: Although Candida arthritis in patient with a hematological malignancy is rare, it still occurred in patient with hypoimmunity. Early diagnosis is difficult due to no distinctive clinical manifestation and hysteresis of pathogenic organism detection. It was found that the knee was the sole joint affected according to the review of fourteen other reports of Candida arthritis in patients with a hematological malignancy but the reason remains unclear. Fungal arthritis must be taken into consideration when dealing with patients with immune deficiency accompanied by arthritis, especially gonarthritis. We emphasize that the most important factors for the successful treatment of fungal arthritis are identified diagnosis and adequate dosage through out the course of treatment.

Filiz Sen - One of the best experts on this subject based on the ideXlab platform.

  • epistaxis and severe weakness in a patient with multiple myeloma therapy related Acute myeloid Leukemia pure erythroid Leukemia
    Archives of Pathology & Laboratory Medicine, 2006
    Co-Authors: Chuanhai Guo, Giorgio Inghirami, Sherif Ibrahim, Filiz Sen
    Abstract:

    Therapy-related Acute myeloid Leukemias arise as a result of cytotoxic chemotherapy and/or radiation therapy. The most common types of Acute myeloid Leukemia arising in this setting are Acute myeloid Leukemia with maturation, and lesser numbers of Acute myeloMonocytic Leukemia, Acute Monocytic Leukemia, Acute erythroLeukemia, or Acute megakaryocytic Leukemia. We present a patient with multiple myeloma who was treated with melphalan and 4 years later developed Acute erythroid Leukemia. The morphologic diagnosis of pure erythroid Leukemia developing in the setting of multiple myeloma may be challenging.

  • increased incidence of trisomy 8 in Acute myeloid Leukemia with skin infiltration Leukemia cutis
    Diagnostic Molecular Pathology, 2000
    Co-Authors: Filiz Sen, Victor G Prieto, Xiao Xiang Zhang, Christopher R Shea, Mazin B Qumsiyeh
    Abstract:

    Anecdotal literature reports and the authors' own observations suggest an association between chromosome 8 aneuploidy and Leukemia cutis. The authors investigated this potential association by using fluorescence in situ hybridization (FISH) directly on skin infiltrates in a series of 11 patients with Acute Monocytic Leukemia (AML). Seven of the 11 patients were aneuploid for chromosome 8 by FISH which was confirmed by dual color hybridization. Six of these seven patients were AML-M4 or M5 and one was M1. The majority of the cases with Leukemia cutis expressed CD4 (90% of cases), CD14 (60%), and/or CD56 (50%) in bone marrow leukemic cells. The data show the utility of examination of skin infiltrates by FISH for the detection of trisomy 8 in Leukemia cutis. They also suggest the importance of trisomy 8 as a factor in predisposition to skin infiltration in AML.

Jingsong He - One of the best experts on this subject based on the ideXlab platform.

  • candida tropicalis arthritis in a patient with Acute Leukemia
    Journal of Experimental Hematology, 2008
    Co-Authors: Xiaorong Hu, Jingsong He, Xiujin Ye, Weiyan Zheng, Wenjun Wu
    Abstract:

    Candida arthritis in patient with hematological malignancy is rare. A case of Candida tropicalis arthritis of knee occurred in a patient with Acute Monocytic Leukemia was reported during the recovery phase of post chemotherapy myelosuppression and agranulocytosis. The patient was diagnosed as Candida tropicalis arthritis of knee according to the Candida tropicalis isolated from the synovial fluid. Itraconazole and amphotericin B were intravenously injected for therapy for 4-5 weeks based on the susceptibility test in vitro, which showed better efficacy. But the arthritis relapsed at 4-6 weeks after the drug withdrawal. The curative effect was found in patient after treatment with fluconazol injection and articular cavity douching with amphotericin B for 8 weeks. In conclusion, although Candida arthritis in patient with hematological malignancy is rare, it still occurred in the patient with hypoimmunity. The treatment emphasis showed be placed on the full dosage and full treatment course of antifungal agent.

  • candida tropicalis arthritis of the knee in a patient with Acute Monocytic Leukemia
    Blood, 2006
    Co-Authors: Jingsong He, Xiujin Ye, Weiyan Zheng, Wenjun Wu, He Huang
    Abstract:

    The patients with malignant hematopathy are the high-risk group of invasive fungal infections (IFI). Candidemia and IFI caused by Candidas in patients with a hematological malignancy are common but Candida arthritis is rare. Here, we reported a case of Candida tropicalis arthritis of the knee that occurred with Acute Monocytic Leukemia during the recovery period of post chemotherapy myelosuppression and agranulocytosis. Case report: A 45-year-old Chinese woman was diagnosed with Acute Monocytic Leukemia with normal caryotype in november 2004. Complete remission was achieved upon completion of 2 courses of induction chemotherapy. Treatment was administered via a Hickman catheter in the left elbow. Two days after phase V consolidation chemotherapy, the patient experienced high fever accompanied by the development of arthritis in the right knee. The diagnosis of Candida tropicalis arthritis of the knee was confirmed by the appearance of Candida tropicalis isolated from the synovial fluid, but no leukemic cells and acid-fast bacilli were found. According to the susceptibility test in vitro, itraconazole and amphotericin B injection were used sequentially for therapy for 4–5 weeks, which effectively inhibited bacterial growth. However, the arthritis relapsed after 4–6 weeks of drug withdrawal. The arthritis was fully resolved after 8 weeks of therapy with fluconazol injection at a dose of 400mg/d and douching articular cavity with amphotericin B once a week. And then sequential therapy with oral fluconazole was commenced. There was no any adverse effect occurrence during the course of treatment. Discussion: Although Candida arthritis in patient with a hematological malignancy is rare, it still occurred in patient with hypoimmunity. Early diagnosis is difficult due to no distinctive clinical manifestation and hysteresis of pathogenic organism detection. It was found that the knee was the sole joint affected according to the review of fourteen other reports of Candida arthritis in patients with a hematological malignancy but the reason remains unclear. Fungal arthritis must be taken into consideration when dealing with patients with immune deficiency accompanied by arthritis, especially gonarthritis. We emphasize that the most important factors for the successful treatment of fungal arthritis are identified diagnosis and adequate dosage through out the course of treatment.

Wenjun Wu - One of the best experts on this subject based on the ideXlab platform.

  • candida tropicalis arthritis in a patient with Acute Leukemia
    Journal of Experimental Hematology, 2008
    Co-Authors: Xiaorong Hu, Jingsong He, Xiujin Ye, Weiyan Zheng, Wenjun Wu
    Abstract:

    Candida arthritis in patient with hematological malignancy is rare. A case of Candida tropicalis arthritis of knee occurred in a patient with Acute Monocytic Leukemia was reported during the recovery phase of post chemotherapy myelosuppression and agranulocytosis. The patient was diagnosed as Candida tropicalis arthritis of knee according to the Candida tropicalis isolated from the synovial fluid. Itraconazole and amphotericin B were intravenously injected for therapy for 4-5 weeks based on the susceptibility test in vitro, which showed better efficacy. But the arthritis relapsed at 4-6 weeks after the drug withdrawal. The curative effect was found in patient after treatment with fluconazol injection and articular cavity douching with amphotericin B for 8 weeks. In conclusion, although Candida arthritis in patient with hematological malignancy is rare, it still occurred in the patient with hypoimmunity. The treatment emphasis showed be placed on the full dosage and full treatment course of antifungal agent.

  • candida tropicalis arthritis of the knee in a patient with Acute Monocytic Leukemia
    Blood, 2006
    Co-Authors: Jingsong He, Xiujin Ye, Weiyan Zheng, Wenjun Wu, He Huang
    Abstract:

    The patients with malignant hematopathy are the high-risk group of invasive fungal infections (IFI). Candidemia and IFI caused by Candidas in patients with a hematological malignancy are common but Candida arthritis is rare. Here, we reported a case of Candida tropicalis arthritis of the knee that occurred with Acute Monocytic Leukemia during the recovery period of post chemotherapy myelosuppression and agranulocytosis. Case report: A 45-year-old Chinese woman was diagnosed with Acute Monocytic Leukemia with normal caryotype in november 2004. Complete remission was achieved upon completion of 2 courses of induction chemotherapy. Treatment was administered via a Hickman catheter in the left elbow. Two days after phase V consolidation chemotherapy, the patient experienced high fever accompanied by the development of arthritis in the right knee. The diagnosis of Candida tropicalis arthritis of the knee was confirmed by the appearance of Candida tropicalis isolated from the synovial fluid, but no leukemic cells and acid-fast bacilli were found. According to the susceptibility test in vitro, itraconazole and amphotericin B injection were used sequentially for therapy for 4–5 weeks, which effectively inhibited bacterial growth. However, the arthritis relapsed after 4–6 weeks of drug withdrawal. The arthritis was fully resolved after 8 weeks of therapy with fluconazol injection at a dose of 400mg/d and douching articular cavity with amphotericin B once a week. And then sequential therapy with oral fluconazole was commenced. There was no any adverse effect occurrence during the course of treatment. Discussion: Although Candida arthritis in patient with a hematological malignancy is rare, it still occurred in patient with hypoimmunity. Early diagnosis is difficult due to no distinctive clinical manifestation and hysteresis of pathogenic organism detection. It was found that the knee was the sole joint affected according to the review of fourteen other reports of Candida arthritis in patients with a hematological malignancy but the reason remains unclear. Fungal arthritis must be taken into consideration when dealing with patients with immune deficiency accompanied by arthritis, especially gonarthritis. We emphasize that the most important factors for the successful treatment of fungal arthritis are identified diagnosis and adequate dosage through out the course of treatment.

Peter Proksch - One of the best experts on this subject based on the ideXlab platform.

  • callyaerins from the marine sponge callyspongia aerizusa cyclic peptides with antitubercular activity
    Journal of Natural Products, 2015
    Co-Authors: Georgios Daletos, Rainer Kalscheuer, Rudolf Hartmann, Nicole J. De Voogd, Victor Wray, Wenhan Lin, Hendrik Koliwerbrandl, Peter Proksch
    Abstract:

    Chemical investigation of the Indonesian sponge Callyspongia aerizusa afforded five new cyclic peptides, callyaerins I-M (1-5), along with the known callyaerins A-G (6-12). The structures of the new compounds were unambiguously elucidated on the basis of one- and two-dimensional NMR spectroscopy and mass spectrometry. In addition, the structures of callyaerins D (9), F (11), and G (12), previously available in only small amounts, have been reinvestigated and revised. All compounds were tested in vitro against Mycobacterium tuberculosis, as well as against THP-1 (human Acute Monocytic Leukemia) and MRC-5 (human fetal lung fibroblast) cell lines, in order to assess their general cytotoxicity. Callyaerins A (6) and B (7) showed potent anti-TB activity with MIC₉₀ values of 2 and 5 μM, respectively. Callyaerin C (8) was found to be less active, with an MIC₉₀ value of 40 μM. Callyaerin A (6), which showed the strongest anti-TB activity, was not cytotoxic to THP-1 or MRC-5 cells (IC₅₀ > 10 μM), which highlights the potential of these compounds as promising anti-TB agents.

  • Callyaerins from the Marine Sponge Callyspongia aerizusa: Cyclic Peptides with Antitubercular Activity
    2015
    Co-Authors: Georgios Daletos, Rainer Kalscheuer, Hendrik Koliwer-brandl, Rudolf Hartmann, Nicole J. De Voogd, Victor Wray, Wenhan Lin, Peter Proksch
    Abstract:

    Chemical investigation of the Indonesian sponge Callyspongia aerizusa afforded five new cyclic peptides, callyaerins I–M (1–5), along with the known callyaerins A–G (6–12). The structures of the new compounds were unambiguously elucidated on the basis of one- and two-dimensional NMR spectroscopy and mass spectrometry. In addition, the structures of callyaerins D (9), F (11), and G (12), previously available in only small amounts, have been reinvestigated and revised. All compounds were tested in vitro against Mycobacterium tuberculosis, as well as against THP-1 (human Acute Monocytic Leukemia) and MRC-5 (human fetal lung fibroblast) cell lines, in order to assess their general cytotoxicity. Callyaerins A (6) and B (7) showed potent anti-TB activity with MIC90 values of 2 and 5 μM, respectively. Callyaerin C (8) was found to be less active, with an MIC90 value of 40 μM. Callyaerin A (6), which showed the strongest anti-TB activity, was not cytotoxic to THP-1 or MRC-5 cells (IC50 > 10 μM), which highlights the potential of these compounds as promising anti-TB agents